Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04545177 · ClinicalTrials.gov registry record · NA

Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue

A NA study of Glioblastoma, sponsored by Case Comprehensive Cancer Center.

Active
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT04545177: Active NA study of Glioblastoma, sponsored by Case Comprehensive Cancer Center.

NCT04545177 is a NA study of Glioblastoma that is active but no longer recruiting, run by Case Comprehensive Cancer Center. The registered enrollment target is 18 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04545177, a NA study of Glioblastoma, is active but no longer recruiting, sponsored by Case Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

Recent experiments are giving researchers insight into the changes (mutations) that occur in an individual brain tumor cell compared to a normal cell. Currently, we do not have enough knowledge about how uniform these changes are throughout a single brain tumor and if different regions of a brain tumor have different groupings of changes. By obtaining multiple samples of the tumor from various regions during surgery, it will allow researchers to better understand these changes, with the hope that they will lead to new discoveries in the diagnosis and treatment of brain tumors.

Primary Outcome

Flow cytometry will be performed to quantify viable cells in a cell suspension. This will be reported as a percentage of live cells of the population

Conditions Studied

Interventions

  • DEVICE NICO Myriad and Tissue Preservation System (TPS)

Study Locations (1)

Ohio

  • Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2020-09-17
Est. Completion 2026-06
Phase NA
Case Comprehensive Cancer Center

407 total trials

What the registry record for NCT04545177 still lists

NCT04545177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which NICO Myriad and Tissue Preservation System (TPS) is the first listed.

NCT04545177 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT04545177 about?

NCT04545177 is a clinical study titled "Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue". Recent experiments are giving researchers insight into the changes (mutations) that occur in an individual brain tumor cell compared to a normal cell. Currently, we do not have enough knowledge about how uniform these changes are throughout a single brain tumor and if different regions of a brain tu...

What is the current status of trial NCT04545177?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2020-09-17. Estimated completion is 2026-06.

What conditions does trial NCT04545177 study?

This clinical trial studies the following conditions: Glioblastoma.

What interventions are being tested in trial NCT04545177?

The interventions under investigation include: NICO Myriad and Tissue Preservation System (TPS) (DEVICE).

Who is sponsoring clinical trial NCT04545177?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04545177 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04545177's enrollment target sits among peer trials

18 159th of 199 higher than 35 of 199 other Glioblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04545177, the US trial registry maintained by the National Library of Medicine. NCT04545177 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.